Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Chengcheng Gong
Observed names:
C Gong,
C. Gong,
Cheng-Cheng Gong
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
ORCID:
0000-0002-5429-0248
Observed ORCID:
0000-0002-5429-0248
OpenAlex ID:
A5056252091
A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer
2017
·
Yannan Zhao
, Chengcheng Gong
, et al.
·
Oncotarget
·
66
PDF
MicroRNA-320a inhibits proliferation and invasion of breast cancer cells by targeting RAB11A.
2015
·
Biyun Wang
, Ziang Yang
, et al.
·
Europe PMC (PubMed Central)
·
56
18F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with 18F-FDG PET/CT
2019
·
Cheng Liu
, Chengcheng Gong
, et al.
·
The Oncologist
·
54
PDF
A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2− metastatic breast cancer
2021
·
Yi Li
, Wei Li
, et al.
·
Therapeutic Advances in Medical Oncology
·
41
A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel
2017
·
Chengcheng Gong
, Zhongyi Yang
, et al.
·
Scientific Reports
·
40
PDF
Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients
2020
·
Zhonghua Tao
, Ting Li
, et al.
·
Frontiers in Oncology
·
39
PDF
Pretreatment 18F-FDG Uptake Heterogeneity Predicts Treatment Outcome of First-Line Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer
2018
·
Chengcheng Gong
, Guang Ma
, et al.
·
The Oncologist
·
29
Phase II study of chidamide in combination with cisplatin in patients with metastatic triple-negative breast cancer
2021
·
Yanchun Meng
, Juan Jin
, et al.
·
Annals of Palliative Medicine
·
25
PDF
Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
2018
·
Yannan Zhao
, Cheng Liu
, et al.
·
Scientific Reports
·
24
PDF
Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by 18F-FES PET
2022
·
Yizhao Xie
, Xinyue Du
, et al.
·
Cancers
·
21
PDF
Clinicopathological Analysis and Treatment of Adult Patients with Inflammatory Myofibroblastic Tumor: A 15-Year Single-Center Study
2023
·
Xin Liu
, Chengcheng Gong
, et al.
·
Cancer Research and Treatment
·
20
PDF
Heterogeneity derived from 18 F‐FDG PET/CT predicts immunotherapy outcome for metastatic triple‐negative breast cancer patients
2022
·
Yizhao Xie
, Cheng Liu
, et al.
·
Cancer Medicine
·
17
Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
2020
·
Yi Li
, Chengcheng Gong
, et al.
·
Frontiers in Oncology
·
16
PDF
Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
2017
·
Chengcheng Gong
, Yannan Zhao
, et al.
·
Oncotarget
·
15
PDF
Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer
2021
·
Yi Li
, Cheng Liu
, et al.
·
International Journal of General Medicine
·
14
PDF
Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study
2021
·
Yannan Zhao
, Ning Xie
, et al.
·
Therapeutic Advances in Medical Oncology
·
13
PDF
Everolimus-Related Pneumonitis in Patients with Metastatic Breast Cancer: Incidence, Radiographic Patterns, and Relevance to Clinical Outcome
2020
·
Chengcheng Gong
, Qin Xiao
, et al.
·
The Oncologist
·
13
PDF
Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs
2025
·
Lei Huang
, Gang Qin
, et al.
·
Nature Communications
·
12
PDF
Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer
2023
·
Shuhui You
, Chengcheng Gong
, et al.
·
Frontiers in Endocrinology
·
12
PDF
Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study
2019
·
Yizhao Xie
, Yannan Zhao
, et al.
·
Scientific Reports
·
12
PDF
Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
2022
·
Chengcheng Gong
, Cheng Liu
, et al.
·
Cancers
·
11
PDF
Phase II trial of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
2021
·
Yizhao Xie
, Chengcheng Gong
, et al.
·
BMC Cancer
·
11
PDF
Abstract 2702: GQ1001 is a next generation HER2-targeting ADC with excellent druggability, safety and potency
2023
·
Lei Huang
, Lili Shi
, et al.
·
Cancer Research
·
10
Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study)
2026
·
Ting Li
, Teng Zhou
, et al.
·
Journal of Clinical Oncology
·
7
PDF
Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
2019
·
Yi Li
, Yannan Zhao
, et al.
·
Scientific Reports
·
7
PDF
Show more works
View as search
Works count:
55
Citation count:
643
H-index:
14
I10-index:
23
Year
Topic
Type